Edition:
United States

ProMetic Life Sciences Inc (PLI.TO)

PLI.TO on Toronto Stock Exchange

2.92CAD
30 Sep 2016
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.92
Open
$2.93
Day's High
$2.93
Day's Low
$2.92
Volume
11,015
Avg. Vol
1,037,864
52-wk High
$3.62
52-wk Low
$1.42

PLI.TO

Chart for PLI.TO

About

ProMetic Life Sciences Inc. (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various... (more)

Overall

Beta: 2.49
Market Cap(Mil.): $1,765.33
Shares Outstanding(Mil.): 604.56
Dividend: --
Yield (%): --

Financials

  PLI.TO Industry Sector
P/E (TTM): -- 37.66 37.54
EPS (TTM): -0.10 -- --
ROI: -31.94 14.54 13.98
ROE: -41.35 15.32 14.88

BRIEF-ProMetic announces the addition of tympanic membrane perforations to its plasminogen's targeted indications

* Will be pursuing tympanic membrane perforations as one of its new plasma-derived plasminogen targeted clinical indications

Sep 06 2016

BRIEF-Prometic Life Sciences's Plasminogen wins FDA fast track status

* Prometic's plasminogen granted fast track designation by the us fda Source text for Eikon: Further company coverage: (Bengaluru Newsroom +1-646-223-8780)

Jun 13 2016

BRIEF-Prometic announces closing of $60 mln bought deal offering of common shares

* Prometic announces closing of $60 million bought deal offering of common shares Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

May 25 2016

BRIEF-Health Canada authorizes ProMetic to proceed with PBI-4050 clinical trial

May 18 ProMetic Life Sciences Inc Says To Commence Clinical Trial Of Its Orally Active Anti

May 18 2016

BRIEF-Prometic Life Sciences Q1 revenue c$5.2 million

* Prometic reports its first quarter 2016 highlights and financial results

May 12 2016

BRIEF-Prometic announces $60 million bought deal offering

* Prometic announces $60 million bought deal offering to fund strategic growth initiatives

May 04 2016

BRIEF-Prometic's drug efficacy further evidenced in Type 2 diabetic and metabolic syndrome clinical trial

* Prometic's PBI-4050: efficacy further evidenced in type 2 diabetic and metabolic syndrome clinical trial

Apr 26 2016

Earnings vs. Estimates